Achilles Therapeutics (ACHL) Competitors $1.04 +0.10 (+10.64%) (As of 09/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ACHL vs. IVA, ASRT, DERM, ALXO, PDSB, SGMT, CKPT, PYRGF, IXHL, and ANIXShould you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Inventiva (IVA), Assertio (ASRT), Journey Medical (DERM), ALX Oncology (ALXO), PDS Biotechnology (PDSB), Sagimet Biosciences (SGMT), Checkpoint Therapeutics (CKPT), PyroGenesis Canada (PYRGF), Incannex Healthcare (IXHL), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Achilles Therapeutics vs. Inventiva Assertio Journey Medical ALX Oncology PDS Biotechnology Sagimet Biosciences Checkpoint Therapeutics PyroGenesis Canada Incannex Healthcare Anixa Biosciences Achilles Therapeutics (NASDAQ:ACHL) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations. Do analysts recommend ACHL or IVA? Achilles Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 284.62%. Inventiva has a consensus price target of $18.00, indicating a potential upside of 757.14%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Achilles Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achilles Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Inventiva 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, ACHL or IVA? Achilles Therapeutics has higher earnings, but lower revenue than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchilles TherapeuticsN/AN/A-$69.67M-$1.60-0.65Inventiva$17.48M6.16-$119.51MN/AN/A Does the MarketBeat Community favor ACHL or IVA? Achilles Therapeutics received 1 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote. CompanyUnderperformOutperformAchilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% InventivaOutperform Votes1680.00% Underperform Votes420.00% Does the media prefer ACHL or IVA? In the previous week, Achilles Therapeutics had 6 more articles in the media than Inventiva. MarketBeat recorded 7 mentions for Achilles Therapeutics and 1 mentions for Inventiva. Inventiva's average media sentiment score of 0.00 beat Achilles Therapeutics' score of -0.04 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achilles Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in ACHL or IVA? 56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ACHL or IVA more profitable? Inventiva's return on equity of 0.00% beat Achilles Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Achilles TherapeuticsN/A -47.24% -41.69% Inventiva N/A N/A N/A Which has more volatility & risk, ACHL or IVA? Achilles Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. SummaryInventiva beats Achilles Therapeutics on 9 of the 14 factors compared between the two stocks. Ad Brownstone ResearchAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowClick here to see why Get Achilles Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHL vs. The Competition Export to ExcelMetricAchilles TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.73M$3.18B$5.51B$8.43BDividend YieldN/A1.95%4.98%4.06%P/E Ratio-0.6528.88143.0418.91Price / SalesN/A269.941,700.1786.54Price / CashN/A148.4537.4331.50Price / Book0.303.954.944.55Net Income-$69.67M-$43.95M$115.12M$225.08M7 Day Performance43.88%-1.08%9.01%3.29%1 Month Performance41.11%23.07%15.36%7.78%1 Year Performance15.85%19.37%33.07%14.53% Achilles Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva1.2611 of 5 stars1.26 / 5 stars$2.21-1.3%$18.00+714.5%-44.6%$115.97M$17.48M0.00100Upcoming EarningsGap DownASRTAssertio2.605 of 5 stars2.61 / 5 stars$1.22-0.4%$3.44+182.9%-49.1%$115.58M$132.19M-0.3120Gap UpDERMJourney Medical3.6293 of 5 stars3.63 / 5 stars$5.46+5.8%$9.38+71.7%N/A$113.19M$79.18M-17.6190News CoverageALXOALX Oncology3.9127 of 5 stars3.91 / 5 stars$2.17-2.3%$14.00+545.2%-56.3%$113.06MN/A-0.5840Short Interest ↑Positive NewsPDSBPDS Biotechnology1.804 of 5 stars1.80 / 5 stars$3.04+1.3%$14.25+368.8%-39.9%$111.50MN/A-2.2420Analyst ForecastSGMTSagimet Biosciences2.1441 of 5 stars2.14 / 5 stars$3.58-3.8%$24.00+570.4%-72.3%$109.80M$2M0.008CKPTCheckpoint Therapeutics3.7819 of 5 stars3.78 / 5 stars$2.38+3.5%$12.00+404.2%+37.3%$107.15M$100,000.00-0.8610PYRGFPyroGenesis Canada0 of 5 stars0.00 / 5 stars$0.58-2.8%N/AN/A$107.05M$9.14M-5.3190IXHLIncannex Healthcare0.326 of 5 stars0.33 / 5 stars$1.68+3.1%N/A+53.2%$106.65M$930,000.000.003Positive NewsANIXAnixa Biosciences3.0116 of 5 stars3.01 / 5 stars$3.33-0.6%$7.00+110.2%-4.2%$106.58M$210,000.00-9.005Analyst ForecastAnalyst RevisionPositive News Related Companies and Tools Related Companies: IVA Alternatives ASRT Alternatives DERM Alternatives ALXO Alternatives PDSB Alternatives SGMT Alternatives CKPT Alternatives PYRGF Alternatives IXHL Alternatives ANIX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACHL) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACHL Stock Alerts